Acute Porphyria Drug Database

A10AE06 - Insulin Degludec
Not porphyrinogenic
NP

Rationale
Insulin degludec has no porphyrinogenic effects.
Chemical description
Antidiabetic pancreatic hormone consisting of polypeptide chains, connected by disulfide bridges.
Metabolism and pharmacokinetics
Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, which are slowly and continuously absorbed into the bloodstream leading to a flat and stable glucose-lowering-effect. Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are inactive.

References

  1. Scientific articles
  2. Muñoz Torres M. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research. Endocrinol Nutr. 2014 Mar;61(3):153-9. PMID 23890782. #3191
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tresiba. #3192

Similar drugs
Explore alternative drugs in similar therapeutic classes A10A / A10AE or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙